{"id":"NCT00997984","sponsor":"Shire","briefTitle":"Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)","officialTitle":"A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11-17","primaryCompletion":"2010-10-09","completion":"2010-10-09","firstPosted":"2009-10-20","resultsPosted":"2011-10-26","lastUpdate":"2021-06-08"},"enrollment":340,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention-Deficit/Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"extended-release guanfacine hydrochloride (SPD503)","otherNames":["Intuniv"]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"extended-release guanfacine hydrochloride","otherNames":["Intuniv"]}],"arms":[{"label":"Extended-release Guanfacine Hydrochloride (SPD503) AM","type":"EXPERIMENTAL"},{"label":"placebo","type":"EXPERIMENTAL"},{"label":"SPD503 PM","type":"EXPERIMENTAL"}],"summary":"The primary purpose is to assess the efficacy of once daily dosing with optimized SPD503 (1, 2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children with ADHD as measured by change from baseline score at endpoint on the ADHD-RS-IV.","primaryOutcome":{"measure":"Change From Baseline in Attention-Deficit/Hyperactivity Disorder-Rating Scale-IV (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)","timeFrame":"Baseline and up to 8 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-10.6,"sd":1.2},{"arm":"SPD503 AM","deltaMin":-20,"sd":1.23},{"arm":"SPD503 PM","deltaMin":-20.4,"sd":1.19},{"arm":"All-Active","deltaMin":-20.2,"sd":0.86}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":46,"countries":["United States","Canada"]},"refs":{"pmids":["23972694","26547425"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":112},"commonTop":["Somnolence","Headache","Sedation","Abdomonal pain upper","Fatigue"]}}